Group 1: Investor Relations Activity - The investor relations activity was conducted on February 18, 2025, via an online meeting [3] - Participants included Anxin Fund Management Co., Ltd., with the company's representative being Ms. Chen Xianghong, the Secretary of the Board and CFO [3] Group 2: Competitive Landscape - Major competitors of Wuxi Jinghai include Tianyao Pharmaceutical, Yuanda Pharmaceutical, Huaheng Biological, Ajinomoto (Japan), Kyowa Hakko (Japan), Evonik (Germany), and CJ CheilJedang (South Korea) [4] Group 3: Customer Concentration - Wuxi Jinghai primarily engages in the R&D, production, and sales of amino acid products, including branched-chain amino acids (isoleucine, valine, leucine), tryptophan, phenylalanine, and proline [5] - The downstream industries for these products encompass pharmaceuticals, food, health products, and cosmetics, with a relatively large market size [5] - The industry concentration is low, and the company's customer base is diverse and dispersed, resulting in a low customer concentration [5]
无锡晶海(836547) - 投资者关系活动记录表